Old Web
English
Sign In
Acemap
>
authorDetail
>
E Michael Lewiecki
E Michael Lewiecki
Katholieke Universiteit Leuven
Denosumab
Osteoporosis
fracture risk
postmenopausal women
Romosozumab
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.
2017
Journal of Bone and Mineral Research
E Michael Lewiecki
Rajani Dinavahi
Marise Lazaretti Castro
Peter R. Ebeling
Jonathan D. Adachi
Akimitsu Miyauchi
Evelien Gielen
Cassandra E. Milmont
Cesar Libanati
Andreas Grauer
Show All
Source
Cite
Save
Citations (0)
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
2017
Arthritis & Rheumatism
E Michael Lewiecki
Rajani Dinavahi
Marise Lazaretti Castro
Peter R. Ebeling
J. Adachi
Akimitsu Miyauchi
Evelien Gielen
Cassandra E. Milmont
Cesar Libanati
Andreas Grauer
Show All
Source
Cite
Save
Citations (0)
1